
October, 4th
3D Signatures Sells 2M Shares to ScreenCell for C$500K
Info+
Oct 04, 2017
NEW YORK (GenomeWeb) – Personalized medicine company 3D Signatures announced late yesterday that it has sold 2 million shares of its common stock in a private placement to French biotechnology company ScreenCell for gross proceeds of C$500,000 (US$400,198).
3DS is developing diagnostic and prognostic tests based on a proprietary platform that analyzes the spatial patterns of chromosomes by tagging and imaging their telomeres. The proceeds from the placement, under which the stock was sold for C$.25 per share, will be used primarily to fund 3DS’ clinical operations, including clinical wages and laboratory expenses. The rest will be used for general working capital.
ScreenCell has been working with 3DS since the company was founded and supplies it with a screening system for the capture and isolation of circulating tumor cells from blood.
“It’s a strong endorsement of 3DS when a major supplier and technology collaborator makes a financial investment in the company,” 3DS CEO Jason Flowerday said in a statement. “ScreenCell is a leader in its field and we look forward to a continued partnership.”
In July, the company filed paperwork with Canadian regulators to privately sell up to 12.5 million shares of its common stock in the US for a total of C$5 million.
September, 28th
ScreenCell Establishment Licence Canada MD class 1
Info+
This Licence is issued in accordance with the Medical Devices Regulation of Food and Drugs Act for the following activities:
Issue Date: 2016-06-02
November, 2nd
ScreenCell sponsors Molecular Med TRI-CON 2016, March 7-9 2016, San Francisco, CA
Info+
http://www.triconference.com/Circulating-Tumor-Cells/
December, 8th
ScreenCell sponsors the CLARA (6th Edition of Industrials-Academics meeting) Lyon, France (December 16, 2014).
Info+
November, 5th
ScreenCell sponsors the CIRCULATE (Circulating Cancer Biomarkers) Boston, MA (November 18-20, 2014).
Info+
Conference Day One
Tuesday, 18th November
11.40 Isolation and Characterization of Circulating Melanoma Cancer Cells by Size Filtration and Fluorescent In Situ Hybridization
Masahiko Yanagita, Postdoctoral Fellow, Dana-Farber Cancer Institute
2.10 Characterization Of Prostate Cancer CTCs By 3D Nuclear Telomere Imaging
Sabine Mai, Director, Genomic Centre for Research and Diagnosis
August, 14th
ACTC 2014 2nd International Symposium on Advances in Circulating Tumor Cells October 8th–11th, 2014, Crete, Greece
Info+
Detection of Circulating Tumor Cells (CTC) in peripheral blood can serve as a “liquid biopsy” approach and has emerged as one of the hottest fields in cancer research. Nowadays, CTC molecular characterization has a strong potential to be translated into individualized targeted treatments. A variety of analytical systems are continuously been developed for CTC isolation, detection and molecular characterization. CTC molecular characterization at the single cell level holds considerable promise for the identification of therapeutic targets and resistance mechanisms in CTCs as well as for the stratification of patients and real-time monitoring of systemic therapies.
The ACTC meeting is focused on the potential of CTC as a liquid biopsy by bringing together researchers and clinicians to discuss practical implementation of CTCs and translate much of the excellent basic research in this field into clinical practice. The most prominent and established researchers in the field will present state of the art research on the biology of metastasis and on the technical advancements in the isolation, detection and molecular characterization of CTCs. Latest findings on the clinical applications of CTCs in real time monitoring of systemic anticancer therapies will be discussed. A particular emphasis will be given on the relationship of CTCs to cancer stem cells and the relevance of recent findings for the development and use of new targeted therapies in oncology.
August, 14th
Innovation Days 2014 The leading partnering meeting in Open Innovation for Life Sciences Paris • October 6-7, 2014
Info+
Innovation Days brings together public and private actors of the life sciences to maximize business opportunities during two days of high level conferences and one-on-one partnering meetings.
January, 23rd
ScreenCell sponsors CIRCULATE Circulating Cancer Biomarkers, February 18-20 2014, Berlin
Info+
February 19th 11.50 am Size-based Technology for Circulating Tumor Cells Isolation: extensive characterization after culture expansion
Georges Uzan, CSO, ScreenCell
January, 23rd
ScreenCell sponsors Molecular Med TRI-CON, February 9-14 2014, San Francisco
Info+
Cancer channel – Circulating Tumor Cells (Spotlight on Clinical Validation)
February 11th 12:00 pm Characterization of Circulating Large Cells Isolated by ScreenCell-Filtration in Renal Tumor Patients
Karoline Lackner, M.D., Professor, Pathology, Institute of Pathology, Medical University of Graz
Circulating non-hematologic cells (CNHCs) – putative CTCs/CTMs – isolated from blood by ScreenCell filtration in 40 patients with renal tumors were characterized. We found that CNHC-clusters with malignant or uncertain malignant cytomorphological features were CD45neg/CD31pos. Array-CGH revealed a balanced genome in 83% of cytomorphologically malignant/uncertain malignant CNHC-clusters whereas 17% showed genomic DNA imbalances not found in the primary tumors. Thus the majority of CNHC-clusters may be of endothelial origin.
November, 13th
JIB 2013 58eme Journées Internationales de Biologie, 13-14-15 Novembre 2013, Paris
Info+
Poster N°34 : J.A. DENIS1, A. PATRONI1,2, D. PEPIN1, N. BENALI-FURET3, J. WECHSLER3, M. BERNARD 1 , M. KAROUI2, J.M. LACORTE 1
EVALUATION DE LA TECHNIQUE SCREENCELL POUR L’ISOLEMENT ET LA CARACTERISATION DES CELLULES TUMORALES CIRCULANTES (CTCS) DANS LE CANCER DU COLON
Dans cette étude, nous avons choisi d’évaluer un dispositif commercialisé par lasociété ScreenCell qui permet d’isoler les cellules tumorales circulantes sur le critèrede leurs tailles grâce à un filtre ayant des pores de 7.5 ±0.36 μm. En effet il a été montré que les CTCs avaient une taille moyenne plus importante que les cellules sanguines. L’avantage de cette méthode est que la fraction cellulaire retenue peut être analysée morphologiquement à l’aide de marqueurs épithéliaux, tels que les cytokératines mais aussi par une analyse moléculaire (ADN ou ARN).
November, 12th
ScreenCell sponsors World CTC USA, November 12-15 2013, Boston
Info+
2.30 pm: 3D Nuclear Telomere Parameters Define CTC Sub-populations
Sabine Mai, Professor, University of Manitoba
September, 25th
ISMRC 9th International Symposium on Minimal Residual Cancer, September 25-27 2013, Paris
Info+
Poster presentation: Dr Naoual Benali, R&D Manager ScreenCell
Ex-vivo Expansion of CTCs in Culture Isolated by Size from Patients with Melanoma
February, 13th
ScreenCell sponsors TriCON 2013 from Feb 13-15 in San Francisco
Info+
November, 12th
ScreenCell sponsors the World CTC Summit in Boston (November 12-15 2012 – Hyatt Regency)
Info+
On November 13th at 2pm, ScreenCell will host a presentation from :
Sabine Mai, Ph.D.
Senior Investigator, Manitoba Institute of Cell Biology,
Professor, University of Manitoba ,
Director, The Genomic Centre for Cancer Research and Diagnosis.
Dr Mai, will present 3D Nuclear Telomere Parameters Define CTC Subpopulations :
June, 18th
ScreenCell participates to Bio Boston from June 18th to 21st
Info+
Boston Convention & Exhibition Center
415, Summer Street Boston, MA 02210, Etats-Unis
HALL A – Booth : 1043
April, 25th
ScreenCell sponsors Berlin’s CTC Summit on April 25th and 26th 2012
Info+
ScreenCell sponsors Berlin’s CTC Summit and will host a presentation from :
Sabine Mai, Ph.D.
Senior Investigator, Manitoba Institute of Cell Biology,
Professor, University of Manitoba ,
Director, The Genomic Centre for Cancer Research and Diagnosis.
Dr Mai, will present 3D Nuclear Telomere Parameters Define CTC Subpopulations :
February, 21st
ScreenCell sponsors TriCON 2012 from Feb 21st to 23rd in San Francisco
Info+
Molecular Med TriCON 2012
February 19-23, 2012
Moscone North Convention Center, San Francisco, CA (USA)
http://www.triconference.com/